nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A3—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0517	0.0726	CbGpPWpGaD
Amphetamine—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0516	0.0724	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0293	0.0412	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.012	0.0168	CbGpPWpGaD
Amphetamine—Injury—Hydrochlorothiazide—nephrolithiasis	0.0115	0.04	CcSEcCtD
Amphetamine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0396	CcSEcCtD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0111	0.0156	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—PTH—nephrolithiasis	0.0111	0.0155	CbGpPWpGaD
Amphetamine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0364	CcSEcCtD
Amphetamine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0362	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0104	0.0145	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0103	0.0145	CbGpPWpGaD
Amphetamine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.01	0.0348	CcSEcCtD
Amphetamine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00965	0.0335	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00963	0.0135	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0096	0.0135	CbGpPWpGaD
Amphetamine—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00951	0.0331	CcSEcCtD
Amphetamine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00841	0.0292	CcSEcCtD
Amphetamine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00833	0.029	CcSEcCtD
Amphetamine—DRD2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00814	0.0114	CbGpPWpGaD
Amphetamine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00807	0.0281	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00806	0.0113	CbGpPWpGaD
Amphetamine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00802	0.0279	CcSEcCtD
Amphetamine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00798	0.0277	CcSEcCtD
Amphetamine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00791	0.0275	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00785	0.011	CbGpPWpGaD
Amphetamine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.0078	0.0271	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00749	0.0105	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—SLC26A1—nephrolithiasis	0.0072	0.0101	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00718	0.0101	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00718	0.0101	CbGpPWpGaD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00714	0.01	CbGpPWpGaD
Amphetamine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00691	0.024	CcSEcCtD
Amphetamine—DRD2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00684	0.0096	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00679	0.00953	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00677	0.0095	CbGpPWpGaD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00664	0.00932	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00628	0.00882	CbGpPWpGaD
Amphetamine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00624	0.0217	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00621	0.00872	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00621	0.00872	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00619	0.00869	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00619	0.00869	CbGpPWpGaD
Amphetamine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00618	0.0215	CcSEcCtD
Amphetamine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00596	0.0207	CcSEcCtD
Amphetamine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00585	0.0203	CcSEcCtD
Amphetamine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00581	0.0202	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00577	0.0081	CbGpPWpGaD
Amphetamine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00562	0.0195	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00544	0.00764	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00544	0.00764	CbGpPWpGaD
Amphetamine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00542	0.0188	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.0054	0.00758	CbGpPWpGaD
Amphetamine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0054	0.0188	CcSEcCtD
Amphetamine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0053	0.0184	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00529	0.00742	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00519	0.0181	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00509	0.00714	CbGpPWpGaD
Amphetamine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00507	0.0176	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00506	0.0071	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00506	0.0071	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00502	0.0175	CcSEcCtD
Amphetamine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00495	0.0172	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00483	0.00678	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00483	0.00678	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00479	0.00672	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00471	0.00661	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00471	0.00661	CbGpPWpGaD
Amphetamine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.0047	0.0163	CcSEcCtD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00469	0.00659	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00469	0.00659	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00468	0.00657	CbGpPWpGaD
Amphetamine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00463	0.0161	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—RGS14—nephrolithiasis	0.00462	0.00648	CbGpPWpGaD
Amphetamine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00462	0.016	CcSEcCtD
Amphetamine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00457	0.0159	CcSEcCtD
Amphetamine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00451	0.0157	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00451	0.00633	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00448	0.00629	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00448	0.00629	CbGpPWpGaD
Amphetamine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00448	0.0156	CcSEcCtD
Amphetamine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00444	0.0154	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00439	0.00617	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00438	0.00614	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00438	0.00614	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00436	0.00612	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00436	0.00612	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00428	0.00601	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00428	0.00601	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00425	0.0148	CcSEcCtD
Amphetamine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00412	0.0143	CcSEcCtD
Amphetamine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.0041	0.0143	CcSEcCtD
Amphetamine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.0041	0.0143	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—PTH—nephrolithiasis	0.00402	0.00564	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC2A9—nephrolithiasis	0.004	0.00561	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00399	0.0056	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.0039	0.00548	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00389	0.00546	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00387	0.00544	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00387	0.00544	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00386	0.00542	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00386	0.00542	CbGpPWpGaD
Amphetamine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00382	0.0133	CcSEcCtD
Amphetamine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00372	0.013	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00366	0.00514	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00366	0.00514	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00365	0.00512	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00365	0.00512	CbGpPWpGaD
Amphetamine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00355	0.0124	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—SLC26A1—nephrolithiasis	0.00351	0.00492	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00347	0.00487	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00345	0.00484	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00344	0.00483	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00343	0.00482	CbGpPWpGaD
Amphetamine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00343	0.0119	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00341	0.00478	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00341	0.00478	CbGpPWpGaD
Amphetamine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.0033	0.0115	CcSEcCtD
Amphetamine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00327	0.0114	CcSEcCtD
Amphetamine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00327	0.0114	CcSEcCtD
Amphetamine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00325	0.0113	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00325	0.00456	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00325	0.00456	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADCY10—nephrolithiasis	0.00321	0.0045	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00316	0.00443	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00316	0.00443	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00315	0.00442	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00315	0.00442	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DGKH—nephrolithiasis	0.00312	0.00438	CbGpPWpGaD
Amphetamine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00308	0.0107	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00304	0.00426	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00302	0.00423	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00302	0.00423	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00301	0.00423	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00301	0.00423	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00277	0.00388	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00277	0.00388	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RGS14—nephrolithiasis	0.00273	0.00383	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00269	0.00377	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00269	0.00377	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00267	0.00375	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00267	0.00375	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00257	0.00361	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00257	0.00361	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00248	0.00349	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00246	0.00345	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00246	0.00345	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00239	0.00336	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00239	0.00336	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00238	0.00335	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00238	0.00335	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00238	0.00334	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00229	0.00322	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00229	0.00322	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PTH—nephrolithiasis	0.00227	0.00319	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00226	0.00317	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00222	0.00312	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00222	0.00312	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00222	0.00311	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00222	0.00311	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00218	0.00305	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00218	0.00305	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PTH—nephrolithiasis	0.00206	0.0029	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00198	0.00278	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00198	0.00278	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00198	0.00277	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00198	0.00277	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00197	0.00276	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00186	0.00261	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00186	0.00261	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DGKH—nephrolithiasis	0.00184	0.00259	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00184	0.00259	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00183	0.00257	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00173	0.00243	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00173	0.00243	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00165	0.00231	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00165	0.00231	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GRHPR—nephrolithiasis	0.00162	0.00228	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00158	0.00222	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00158	0.00222	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00157	0.0022	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00154	0.00217	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00154	0.00217	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00153	0.00215	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00153	0.00215	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AGXT—nephrolithiasis	0.00145	0.00203	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GRHPR—nephrolithiasis	0.00137	0.00193	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00137	0.00192	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00137	0.00192	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00135	0.00189	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CHRM3—nephrolithiasis	0.00133	0.00187	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00123	0.00173	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC26A1—nephrolithiasis	0.00123	0.00173	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APRT—nephrolithiasis	0.00123	0.00173	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AGXT—nephrolithiasis	0.00123	0.00172	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTH—nephrolithiasis	0.00122	0.00171	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00119	0.00166	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00109	0.00153	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RGS14—nephrolithiasis	0.00108	0.00151	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC26A1—nephrolithiasis	0.00104	0.00146	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APRT—nephrolithiasis	0.00104	0.00146	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00102	0.00144	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTH—nephrolithiasis	0.000937	0.00132	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AQP1—nephrolithiasis	0.000877	0.00123	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000801	0.00112	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CHRM3—nephrolithiasis	0.000793	0.00111	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GRHPR—nephrolithiasis	0.000791	0.00111	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADCY10—nephrolithiasis	0.000748	0.00105	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AQP1—nephrolithiasis	0.000742	0.00104	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DGKH—nephrolithiasis	0.000727	0.00102	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AGXT—nephrolithiasis	0.000705	0.00099	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CHRM3—nephrolithiasis	0.000671	0.000942	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RGS14—nephrolithiasis	0.000636	0.000893	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SPP1—nephrolithiasis	0.000612	0.000859	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APRT—nephrolithiasis	0.0006	0.000842	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC26A1—nephrolithiasis	0.0006	0.000842	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000579	0.000813	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PTH—nephrolithiasis	0.00053	0.000744	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000526	0.000738	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTH—nephrolithiasis	0.000481	0.000675	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000444	0.000623	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00043	0.000603	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DGKH—nephrolithiasis	0.00043	0.000603	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AQP1—nephrolithiasis	0.000427	0.0006	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000396	0.000555	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CHRM3—nephrolithiasis	0.000387	0.000543	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000336	0.000472	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000336	0.000472	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CHRM3—nephrolithiasis	0.000311	0.000436	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTH—nephrolithiasis	0.000284	0.000399	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.00024	0.000336	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000217	0.000304	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SPP1—nephrolithiasis	0.000143	0.0002	CbGpPWpGaD
